KRYS – Krystal Biotech, Inc.
KRYS — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
11.4
Margin Of Safety %
-6
Put/Call OI Ratio
0.37
EPS Next Q Diff
0.05
EPS Last/This Y
0.65
EPS This/Next Y
2.85
Price
264.33
Target Price
324.78
Analyst Recom
1.17
Performance Q
5.95
Upside
-9.4%
Beta
0.55
Ticker: KRYS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | KRYS | 258.61 | 0.45 | 5.83 | 4684 |
| 2026-03-10 | KRYS | 260.79 | 0.45 | 0.07 | 4698 |
| 2026-03-11 | KRYS | 254.85 | 0.45 | 0.04 | 4716 |
| 2026-03-12 | KRYS | 251.34 | 0.45 | 0.12 | 4730 |
| 2026-03-13 | KRYS | 251.31 | 0.45 | 0.11 | 4730 |
| 2026-03-17 | KRYS | 256.01 | 0.34 | 0.35 | 5741 |
| 2026-03-18 | KRYS | 251.01 | 0.34 | 0.00 | 5752 |
| 2026-03-19 | KRYS | 258.05 | 0.34 | 0.96 | 5745 |
| 2026-03-20 | KRYS | 251.46 | 0.33 | 0.21 | 5753 |
| 2026-03-23 | KRYS | 249.7 | 0.54 | 0.01 | 3790 |
| 2026-03-24 | KRYS | 247.11 | 0.38 | 0.05 | 4818 |
| 2026-03-25 | KRYS | 254.45 | 0.38 | 0.03 | 4833 |
| 2026-03-26 | KRYS | 251.4 | 0.38 | 2.14 | 4825 |
| 2026-03-27 | KRYS | 245.69 | 0.38 | 0.08 | 4824 |
| 2026-03-30 | KRYS | 246.66 | 0.38 | 0.06 | 4841 |
| 2026-03-31 | KRYS | 258.44 | 0.38 | 0.53 | 4826 |
| 2026-04-01 | KRYS | 259.03 | 0.38 | 0.00 | 4819 |
| 2026-04-02 | KRYS | 260.83 | 0.38 | 1.71 | 4820 |
| 2026-04-06 | KRYS | 261.41 | 0.38 | 2.67 | 4818 |
| 2026-04-07 | KRYS | 263.81 | 0.38 | 0.00 | 4812 |
| 2026-04-08 | KRYS | 264.55 | 0.37 | 0.01 | 4890 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | KRYS | 258.49 | 15.9 | 57.9 | 7.83 |
| 2026-03-10 | KRYS | 260.70 | 15.9 | 55.2 | 7.83 |
| 2026-03-11 | KRYS | 254.91 | 15.9 | 47.7 | 7.83 |
| 2026-03-12 | KRYS | 251.16 | 15.9 | 49.6 | 7.83 |
| 2026-03-13 | KRYS | 247.37 | 15.9 | 49.4 | 7.83 |
| 2026-03-17 | KRYS | 256.17 | 15.9 | 59.0 | 7.83 |
| 2026-03-18 | KRYS | 251.07 | 15.9 | 48.3 | 7.83 |
| 2026-03-19 | KRYS | 258.04 | 15.9 | 60.1 | 7.83 |
| 2026-03-20 | KRYS | 251.68 | 15.9 | 47.3 | 7.83 |
| 2026-03-23 | KRYS | 249.52 | 15.9 | 51.4 | 7.83 |
| 2026-03-24 | KRYS | 246.99 | 15.9 | 50.8 | 7.83 |
| 2026-03-25 | KRYS | 254.80 | 15.9 | 61.1 | 7.83 |
| 2026-03-26 | KRYS | 251.57 | 15.9 | 50.0 | 7.83 |
| 2026-03-27 | KRYS | 245.71 | 15.9 | 47.7 | 7.83 |
| 2026-03-30 | KRYS | 246.76 | 21.4 | 54.5 | 7.71 |
| 2026-03-31 | KRYS | 258.09 | 22.7 | 64.3 | 7.73 |
| 2026-04-01 | KRYS | 258.91 | 22.7 | 53.5 | 7.73 |
| 2026-04-02 | KRYS | 260.63 | 22.7 | 54.9 | 7.73 |
| 2026-04-06 | KRYS | 261.73 | 22.7 | 54.1 | 7.73 |
| 2026-04-07 | KRYS | 264.08 | 22.7 | 55.5 | 7.73 |
| 2026-04-08 | KRYS | 264.33 | 22.7 | 53.5 | 7.73 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | KRYS | -6.12 | -0.13 | 10.89 |
| 2026-03-10 | KRYS | -6.12 | -0.13 | 10.89 |
| 2026-03-11 | KRYS | -6.12 | -0.13 | 11.64 |
| 2026-03-12 | KRYS | -6.12 | -0.13 | 11.64 |
| 2026-03-13 | KRYS | -6.12 | -0.13 | 11.64 |
| 2026-03-17 | KRYS | -6.12 | -1.38 | 11.64 |
| 2026-03-18 | KRYS | -6.12 | -1.38 | 11.64 |
| 2026-03-19 | KRYS | -6.12 | -1.38 | 11.64 |
| 2026-03-20 | KRYS | -6.12 | -1.38 | 11.64 |
| 2026-03-23 | KRYS | -6.12 | -1.42 | 11.64 |
| 2026-03-24 | KRYS | -6.12 | -1.42 | 11.64 |
| 2026-03-25 | KRYS | -6.12 | -1.42 | 11.40 |
| 2026-03-26 | KRYS | -6.12 | -1.42 | 11.40 |
| 2026-03-27 | KRYS | -6.12 | -1.42 | 11.40 |
| 2026-03-30 | KRYS | -6.12 | -1.35 | 11.40 |
| 2026-03-31 | KRYS | -6.12 | -1.35 | 11.40 |
| 2026-04-01 | KRYS | -6.12 | -1.35 | 11.40 |
| 2026-04-02 | KRYS | -6.12 | -1.35 | 11.40 |
| 2026-04-06 | KRYS | -6.12 | -1.35 | 11.40 |
| 2026-04-07 | KRYS | -6.12 | -1.35 | 11.40 |
| 2026-04-08 | KRYS | -6.12 | -1.35 | 11.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.7
Avg. EPS Est. Current Quarter
1.47
Avg. EPS Est. Next Quarter
1.75
Insider Transactions
-6.12
Institutional Transactions
-1.35
Beta
0.55
Average Sales Estimate Current Quarter
112
Average Sales Estimate Next Quarter
127
Fair Value
247.8
Quality Score
90
Growth Score
39
Sentiment Score
72
Actual DrawDown %
11.4
Max Drawdown 5-Year %
-51.3
Target Price
324.78
P/E
38.6
Forward P/E
26.65
PEG
1.05
P/S
19.85
P/B
6.32
P/Free Cash Flow
40.89
EPS
6.84
Average EPS Est. Cur. Y
7.73
EPS Next Y. (Est.)
10.58
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
52.64
Relative Volume
0.99
Return on Equity vs Sector %
-10.5
Return on Equity vs Industry %
6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.13
EBIT Estimation
53.5
◆
KRYS
Healthcare
$264.22
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
55.6
Range 1M
73.6%
Sup Dist
1.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
11.7%
EPS NY
29.8%
52W%
80.3%
Long-Term Value
Quality companies, undervalued
WATCH
🟡 HOLD
+22.8% upside
Upside
+22.8%
Quality
90
MoS
-6%
Krystal Biotech, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 295
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
KRYS
Latest News
—
Caricamento notizie per KRYS…
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading